<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20200410047011N2</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-12-13</date_registration>
      <primary_sponsor>Artesh University of Medical Sciences</primary_sponsor>
      <public_title>Designing and manufacturing of an inflatable thigh strap and evaluating its effectiveness on hemostasis during sheet removal and prevention of complications after transfemoral coronary angiography.</public_title>
      <acronym></acronym>
      <scientific_title>Designing and manufacturing of an inflatable thigh strap and evaluating its effectiveness on hemostasis during sheet removal and prevention of complications after transfemoral coronary angiography in patients referring to hospital.</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2020-10-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>80</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/66186</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: 80 patients were included in the study by available sampling method and were 
divided into experimental and control groups based on the day of visit by coin toss.
In this way, the patients who were visited on Sundays were included in the 
experimental group and they used an inflatable thigh strap, and the patients who 
visited on Mondays were in the control group and used sandbags according to the 
hospital routine.</study_design>
      <phase>N/A</phase>
      <hc_freetext>patients with coronary artery disease undergoing transfemoral coronary angiography.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: In the test group, an inflatable thigh starp was used to maintain hemostasis and prevent bleeding and hematoma immediately after the removal of the femoral sheath and hemostasis by hand in the Catheterization Laboratory by a trained nurse according to the protocol determined based on point pressure at the puncture site of the artery, the femoral was closed. The tourniquet was left in place for 4 to 6 hours and then opened. All procedures were performed under the supervision of a physician. Intervention 2: Control group: according to the hospital routine, a sandbag was used instead of an inflatable thigh strap. The weight of the sandbag was 2.5 kg, which was placed in the puncture site of the femoral artery for 6 hours. In all stages, patients of the control group had to keep their legs straight. When the patient was in a semi-sitting position, a pillow was placed on the patient’s back.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
This study was approved by the Ethics Committee of Aja University of Medical 
Sciences (code IR.AJAUMS.REC.1399.133). The provisions of the Declaration of 
Helsinki were observed in this study. Patients entered the study voluntarily and could 
withdraw from the study whenever they wished. Also, the purpose of the study was 
explained to the patients and written informed consent was obtained from all 
patients. The researchers were obliged to ensure that the patients did not suffer 
physical harm and all possible side effects of the intervention were monitored and, 
if necessary, appropriate measures were replaced. The confidentiality of all data and 
the confidentiality of the information sources used were also observed.

When:
6 months after printig results

To whom:
This study was approved by the Ethics Committee of Aja University of Medical 
Sciences (code IR.AJAUMS.REC.1399.133). The provisions of the Declaration of 
Helsinki were observed in this study. Patients entered the study voluntarily and could 
withdraw from the study whenever they wished. Also, the purpose of the study was 
explained to the patients and written informed consent was obtained from all 
patients. The researchers were obliged to ensure that the patients did not suffer 
physical harm and all possible side effects of the intervention were monitored and, 
if necessary, appropriate measures were replaced. The confidentiality of all data and 
the confidentiality of the information sources used were also observed.

Conditions:
This study was approved by the Ethics Committee of Aja University of Medical 
Sciences (code IR.AJAUMS.REC.1399.133). The provisions of the Declaration of 
Helsinki were observed in this study. Patients entered the study voluntarily and could 
withdraw from the study whenever they wished. Also, the purpose of the study was 
explained to the patients and written informed consent was obtained from all 
patients. The researchers were obliged to ensure that the patients did not suffer 
physical harm and all possible side effects of the intervention were monitored and, 
if necessary, appropriate measures were replaced. The confidentiality of all data and 
the confidentiality of the information sources used were also observed.

Where to obtain:
Hojjat Niknam Sarabi, +98 9125574438, offface92@gmail.com

How to obtain:
Send email to the responsible author, confirmation by authors, confirmation by army univarsity of medical sciences, provide data

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Hojjat Niknam Sarabi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Army 502 Haspital, Taleghani Ave, Junc Bahar North st, TEHRAN, IRAN</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1571755511</zip>
        <telephone>+98 21 8830 7020</telephone>
        <email>Offface92@gmail.com</email>
        <affiliation>Artesh University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Hojjat Niknam Sarabi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Army 502 Haspital, Taleghani Ave, Junc Bahar North st, TEHRAN, IRAN</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1571755511</zip>
        <telephone>+98 21 8830 7020</telephone>
        <email>Offface92@gmail.com</email>
        <affiliation>Artesh University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>being alert
not suffering from hemophilia and coagulation disorders
age between 45 and 70 years
candidate for femoral angiography</inclusion_criteria>
      <agemin>45 years</agemin>
      <agemax>70 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>refusal to continue cooperation
the occurrence of complications such as bleeding
hematoma, and abnormal pain during the intervention
use of painkillers or narcotics before, during, and after transfemoral coronary angiography.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>Y84.0</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Cardiac catheterization as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Devices</i_code>
      <i_code>Treatment - Devices</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: In the test group, an inflatable thigh starp was used to maintain hemostasis and prevent bleeding and hematoma immediately after the removal of the femoral sheath and hemostasis by hand in the Catheterization Laboratory by a trained nurse according to the protocol determined based on point pressure at the puncture site of the artery, the femoral was closed. The tourniquet was left in place for 4 to 6 hours and then opened. All procedures were performed under the supervision of a physician.</i_keyword>
      <i_keyword>Control group: according to the hospital routine, a sandbag was used instead of an inflatable thigh strap. The weight of the sandbag was 2.5 kg, which was placed in the puncture site of the femoral artery for 6 hours. In all stages, patients of the control group had to keep their legs straight. When the patient was in a semi-sitting position, a pillow was placed on the patient’s back.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Groin pain: groin pain refers to a feeling of discomfort in the area where the abdomen ends and the legs begin. Timepoint: Three trained and experienced nurses as researcher’s assistants using a chart (before and immediately after closing the FemoStop device, 15 minutes, one hour, two hours, two and a half hours, three hours, three hours and a half, four hours, four and a half hours, five hours, and six hours after closing the FemoStop device, totally of 12 times) recorded and reported all possible complications. Method of measurement: The Visual Analog Scale will be used to measure groin pain. The Visual Analog Scale is used to measure pain. The visual analog scale is the evaluation of pain intensity as a 10 cm horizontal line numbered from 0 to 10 (zero indicates the absence of pain and 10 indicates the most severe pain possible).</prim_outcome>
      <prim_outcome>Hematoma: Localized bleeding outside the blood vessels, which occurs due to illness or trauma, including injury or surgery, and may lead to continued bleeding from broken capillaries. The hematoma is benign and initially spreads as fluid between tissues, including the interstitial sacs, which may coagulate and solidify in the blood vessels before reabsorption. Timepoint: Three trained and experienced nurses as researcher’s assistants using a chart (before and immediately after closing the FemoStop device, 15 minutes, one hour, two hours, two and a half hours, three hours, three hours and a half, four hours, four and a half hours, five hours, and six hours after closing the FemoStop device, totally of 12 times) recorded and reported all possible complications. Method of measurement: The Christensen scale was used to measure hematoma.</prim_outcome>
      <prim_outcome>Leg pain: Prickle, cramping, fatigue and sometimes burning in the legs caused by poor blood circulation in the arteries of the legs. Timepoint: Three trained and experienced nurses as researcher’s assistants using a chart (before and immediately after closing the FemoStop device, 15 minutes, one hour, two hours, two and a half hours, three hours, three hours and a half, four hours, four and a half hours, five hours, and six hours after closing the FemoStop device, totally of 12 times) recorded and reported all possible complications. Method of measurement: The Visual Analog Scale will be used to measure leg pain. The Visual Analog Scale is used to measure pain. The visual analog scale is the evaluation of pain intensity as a 10 cm horizontal line numbered from 0 to 10 (zero indicates the absence of pain and 10 indicates the most severe pain possible).</prim_outcome>
      <prim_outcome>Bleeding: Any bleeding that comes out of the circulatory system due to damage to the blood vessels is called bleeding. Bleeding may be due to vascular disorders, platelets, coagulation factors, coagulation inhibitors, exacerbation of fibrinolysis, or a combination of these factors. Typically, a healthy person can lose 10 to 15% of their total blood volume without serious medical problems. Tolerate. Timepoint: Three trained and experienced nurses as researcher’s assistants using a chart (before and immediately after closing the FemoStop device, 15 minutes, one hour, two hours, two and a half hours, three hours, three hours and a half, four hours, four and a half hours, five hours, and six hours after closing the FemoStop device, totally of 12 times) recorded and reported all possible complications. Method of measurement: En The amount of blood loss will be calculated based on the amount of bleeding based on the number of blood-soaked gases. Given that each 4 in 4 blood gasses in blood is about 10 ml of blood, then the amount of bleeding during 6 hours calculated by multiplying the number of gases collected in 10 Will take.</prim_outcome>
      <prim_outcome>Prothrombin time (PT), Partial thromboplastin time (PTT), international normalized ratio (INR). Timepoint: Before intervention. Method of measurement: Laboratory indicators were measured in the hospital laboratory.</prim_outcome>
      <prim_outcome>Hemodynamic indicators (systolic and diastolic blood pressure, temperature, respiratory rate, heart rate, and arterial oxygen saturation (Sao2)). Timepoint: Three trained and experienced nurses as researcher’s assistants using a chart (before and immediately after closing the FemoStop device, 15 minutes, one hour, two hours, two and a half hours, three hours, three hours and a half, four hours, four and a half hours, five hours, and six hours after closing the FemoStop device, totally of 12 times) recorded and reported all possible complications. Method of measurement: The hemodynamic indicators of the patients were recorded by the monitoring device. The temperature was measured with a thermometer.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Artesh University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2020-10-12</approval_date>
        <contact_name>Army University of Medical Sciences</contact_name>
        <contact_address>Etemadzade st, Ave Fatemi, TEHRAN, IRAN Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
